Open AccessDose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
Author(s) -
Qing Li,
Jiani Wang,
Yuxin Mu,
Tongtong Zhang,
Ying Han,
Jiayu Wang,
Qiao Li,
Yang Luo,
Fei Ma,
Ying Fan,
Pin Zhang,
Binghe Xu
Publication year - 2020
Publication title -
chinese journal of cancer research/chinese journal of cancer research
Language(s) - English
Resource type - Journals
eISSN - 1993-0631
pISSN - 1000-9604
DOI - 10.21147/j.issn.1000-9604.2020.04.06
Subject(s) - epirubicin , medicine , paclitaxel , carboplatin , hazard ratio , breast cancer , cyclophosphamide , population , clinical endpoint , triple negative breast cancer , oncology , confidence interval , chemotherapy , gastroenterology , urology , cancer , randomized controlled trial , cisplatin , environmental health
The objective of this open-label, randomized study was to compare dose-dense paclitaxel plus carboplatin (PCdd) with dose-dense epirubicin and cyclophosphamide followed by paclitaxel (ECdd-P) as an adjuvant chemotherapy for early triple-negative breast cancer (TNBC).